Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 86M | 87M | 39M | 32M | 45M |
| Gross Profit | 86M | 87M | 18M | 26M | 39M |
| Operating Income | 86M | 85M | -5M | -105M | 65M |
| EBITDA | 86M | 87M | 50M | -102M | 69M |
| Net Income | 86M | 85M | 22M | -105M | 65M |
| EPS (Diluted) | — | — | — | — | — |
Financial Services
Live Price
Offline$18.99
+0.53% today
1Y Change
+46.00%
Window
Jun 25, 2025 → Jun 23, 2026
Coverage: 249 bars · Jun 25, 2025 → Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tekla Life Sciences Investors (HQL) is a Financial Services stock with a market cap of $530.00M and listed on NYSE. The stock last traded around $18.99 and up 46.0% across the available one-year price window (Jun 25, 2025 → Jun 23, 2026). Baseline metrics include revenue growth of -0.3%, EPS growth of -2.6%, a dividend yield of 10.9%. What stands out right now is revenue -0.3%, EPS -2.6%, free cash flow 0.0% with operating margin 286.9% and ROIC 16.6%. The dividend matters to the case here, with a current yield around 10.9%. Valuation already assumes a fairly strong business story at P/E 5.9 and price/sales 17.8. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines HQL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Financial Services peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HQL
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HQL Max Drawdown
-10.59%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for HQL and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$45.0M
+41.3% YoY
FY Net Income
$64.5M
+161.7% YoY
Free Cash Flow
$0.0
Revenue Growth
-0.3%
EPS Growth
-2.6%
Gross Margin
30.8%
Net Margin
286.9%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 86M | 87M | 39M | 32M | 45M |
| Gross Profit | 86M | 87M | 18M | 26M | 39M |
| Operating Income | 86M | 85M | -5M | -105M | 65M |
| EBITDA | 86M | 87M | 50M | -102M | 69M |
| Net Income | 86M | 85M | 22M | -105M | 65M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 76K | 0 | 477 | 445 | 990 |
| Total Assets | 515M | 461M | 403M | 415M | 534M |
| Total Liabilities | 2M | 889K | 667K | 17M | 11M |
| Shareholder Equity | 514M | 460M | 402M | 398M | 523M |
| Total Debt | 0 | 0 | 0 | 11M | 1M |
| Net Debt | -76K | 0 | -477 | 11K | 1M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
0
Capital Expenditures
0
Free Cash Flow
0
Key ratios
Gross Margin
30.8%
Operating Margin
286.9%
Net Margin
286.9%
ROE
18.8%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.